{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:01:51Z","timestamp":1768345311144,"version":"3.49.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"15","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2016,10,12]]},"DOI":"10.1080\/14656566.2016.1234609","type":"journal-article","created":{"date-parts":[[2016,9,10]],"date-time":"2016-09-10T21:52:19Z","timestamp":1473544339000},"page":"2115-2124","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Pimavanserin for the treatment of Parkinson\u2019s disease psychosis"],"prefix":"10.1080","volume":"17","author":[{"given":"Ines","family":"Chendo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim J","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000068010.82167.CF"},{"key":"CIT0002","volume-title":"Neurological disorders: public health challenges","author":"World Health Organization","year":"2006"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22643"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.07.005"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-5006-1"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060542"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.587122"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e3283577ed1"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.166"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1002\/gps.389"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2227"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01548.x"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21091"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01392-6"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.3109\/00207450903222758"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20474"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21116"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S5335"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260060.60870.89"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401003"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00860-0"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181c47168"},{"key":"CIT0023","volume-title":"Parkinson\u2019s disease: national clinical guideline for diagnosis and management in primary and secondary care","author":"National Collaborating Centre for Chronic Conditions (UK)","year":"2006"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23884"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2012.03866.x"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d55f24"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000215428.46057.3d"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21077"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.15041"},{"key":"CIT0032","volume-title":"Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics","year":"2016"},{"key":"CIT0033","first-page":"268","volume":"299","author":"Weiner DM","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"CIT0034","first-page":"815","volume":"4","author":"Weiner DM","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.35"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-014-1293-3"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.84947"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.097006"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e3283566082"},{"key":"CIT0040","volume-title":"Nuplazid Tm (Pimavanserin) sponsor background information for a meeting of the psychopharmacologic drugs advisory committee on 29 March 2016","author":"ACADIA Pharmaceuticals","year":"2016"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e32834aff98"},{"key":"CIT0043","author":"Hubbard D","year":"2013","journal-title":"Behav Pharmacol"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007299431"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007299361"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145707007869"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.176"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"CIT0051","unstructured":"Mills RG, Williams H, Bahr D Optimization of phase III study design for pimavanserin in the treatment of Parkinson\u2019s disease psychosis. Abstract, Association of Parkinsonism and Related Disorders\u2019 XIX World Congress on Parkinson\u2019s Disease and Related Disorders. 2011 Dec 11\u201314; Shanghai, China."},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.07.029"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1517\/14656560802532707"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.2174\/156802608784936700"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2010.10.004"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.819345"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150818"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2015.51.11.2404001"},{"key":"CIT0060","volume-title":"Food and Drug Administration. FDA approves first drug to treat hallucinations and delusions associated with Parkinson\u2019s disease","year":"2016"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2016.1234609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T19:17:42Z","timestamp":1481656662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2016.1234609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":55,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2016,9,26]]},"published-print":{"date-parts":[[2016,10,12]]}},"alternative-id":["10.1080\/14656566.2016.1234609"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2016.1234609","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}